Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
Amgen acquires ChemoCentryx in $3.7bn cash deal
an umbrella term for a group of multi-system autoimmune diseases with small vessel inflammation – in combination with standard therapy. ... The treatment is also approved in major markets outside the US, including the EU and Japan.
Latest news
-
AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
have previously received treatment using platinum-based chemotherapy and PD-(L) 1 inhibitors. ... Studies of Monalizumab will continue, with trials focusing on investigating its treatment capacity in a variety of combination strategies in different
-
Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma
The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS. ... The treatment combination is the first immunotherapy in over ten years to be made available via the NHS for the treatment of untreated
-
NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients
Novartis has announced that Piqray (alpelisib) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with Faslodex (fulvestrant) for the treatment of advanced ... following endocrine therapy as
-
MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival. ... the combination treatment was similar to that of earlier clinical trials.
-
Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer
The trial showed that adjuvant treatment using Verzenios in combination with endocrine therapy decreased the risk of breast cancer recurrence by 32%. ... The availability of the combination treatment on the NHS is supported by interim funding from the
More from news
Approximately 0 fully matching, plus 328 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
-
Pharma deals during July 2014
The acquisition of Almirall's respiratory business enhances AZ's respiratory franchise bringing a portfolio of marketed and developmental single and combination products for the treatment of asthma and COPD. ... tremelimumab. Existing partners
-
Interview: AstraZeneca's Susan Galbraith
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
